PMID- 10762673
OWN - NLM
STAT- MEDLINE
DCOM- 20000517
LR  - 20220331
IS  - 0014-2999 (Print)
IS  - 0014-2999 (Linking)
VI  - 392
IP  - 3
DP  - 2000 Mar 31
TI  - The role of fractalkine in the recruitment of monocytes to the endothelium.
PG  - 189-95
AB  - Recombinant fractalkine possesses both chemoattractive and adhesive properties in 
      vitro. Previous studies have demonstrated an upregulation of this molecule on the 
      membranes of activated human endothelial cells and hypothesised that fractalkine 
      plays a role in the recruitment and adherence of monocytes to the activated 
      endothelium. Here we present data analysing both the adhesive and chemoattractive 
      properties of this chemokine expressed by activated human umbilical vein 
      endothelial cells. We demonstrate that both recombinant fractalkine and 
      endogenously produced fractalkine function as adhesion molecules, tethering 
      monocytes to the endothelium. However, our data demonstrate that although 
      recombinant fractalkine has the potential to function as a potent monocyte 
      chemoattractant, the endogenous fractalkine cleaved from activated human 
      umbilical vein endothelial cells is not responsible for the observed chemotaxis 
      in this model. Instead, we show that monocyte chemoattractant protein-1 (MCP-1), 
      secreted from the activated human umbilical vein endothelial cells, is 
      responsible for the chemotaxis of these monocytes.
FAU - Chapman, G A
AU  - Chapman GA
AD  - Department of Neuroscience, SmithKline Beecham Pharmaceuticals, Coldharbour Road, 
      Harlow, Essex, UK.
FAU - Moores, K E
AU  - Moores KE
FAU - Gohil, J
AU  - Gohil J
FAU - Berkhout, T A
AU  - Berkhout TA
FAU - Patel, L
AU  - Patel L
FAU - Green, P
AU  - Green P
FAU - Macphee, C H
AU  - Macphee CH
FAU - Stewart, B R
AU  - Stewart BR
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (CX3CL1 protein, human)
RN  - 0 (Chemokine CX3CL1)
RN  - 0 (Chemokines, CX3C)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Chemotactic Factors)
RN  - 0 (Membrane Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Blotting, Western
MH  - Cell Adhesion/drug effects
MH  - Cell Line
MH  - Chemokine CX3CL1
MH  - *Chemokines, CX3C
MH  - Chemokines, CXC/genetics/pharmacology/*physiology
MH  - Chemotactic Factors/physiology
MH  - Chemotaxis/drug effects
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/cytology/drug effects/*physiology
MH  - Humans
MH  - Membrane Proteins/genetics/pharmacology/*physiology
MH  - Monocytes/*cytology/drug effects
MH  - RNA, Messenger/genetics/metabolism
MH  - Recombinant Proteins/pharmacology
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - Umbilical Veins/cytology/metabolism
EDAT- 2000/04/14 09:00
MHDA- 2000/05/20 09:00
CRDT- 2000/04/14 09:00
PHST- 2000/04/14 09:00 [pubmed]
PHST- 2000/05/20 09:00 [medline]
PHST- 2000/04/14 09:00 [entrez]
AID - S0014299900001175 [pii]
AID - 10.1016/s0014-2999(00)00117-5 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2000 Mar 31;392(3):189-95. doi: 10.1016/s0014-2999(00)00117-5.